Wataru Mimura
Overview
Explore the profile of Wataru Mimura including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
39
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shono A, Morihiro A, Harada N, Seposo X, Mimura W, Hoshi S, et al.
Int J Pharm Pract
. 2025 Feb;
PMID: 39937129
Objective: Testing with fingertip blood sampling, including HbA1c testing, has been available in community pharmacies in Japan since 2014. In 2016, the Mihara Pharmacy Association in Hiroshima Prefecture, in collaboration...
2.
Chikamochi T, Ishiguro C, Mimura W, Maeda M, Murata F, Fukuda H
Pharmacoepidemiol Drug Saf
. 2024 Oct;
33(11):e70032.
PMID: 39449609
Purpose: We validated claims-based algorithms using the International Classification of Diseases, Tenth Revision (ICD-10) to identify patients with the first-ever coronavirus disease (COVID-19) onset between May 2020 and August 2022....
3.
Mimura W, Shinjo D, Isayama T, Fushimi K
Paediatr Perinat Epidemiol
. 2024 Sep;
38(8):679-688.
PMID: 39307949
Background: Hospital-level and international variations exist in the management strategies of bronchopulmonary dysplasia (BPD). However, studies evaluating hospital-level variations in the respiratory outcomes of pre-term infants associated with differing management...
4.
Mimura W, Ishiguro C, Maeda M, Murata F, Fukuda H
Hum Vaccin Immunother
. 2024 May;
20(1):2350091.
PMID: 38757631
Although previous studies have shown no increased mortality risk after the primary series of COVID-19 mRNA vaccines, reports on booster doses are lacking. This study aimed to evaluate mortality risk...
5.
Ishiguro C, Mimura W, Terada J, Matsunaga N, Ishiwari H, Hoshimoto H, et al.
J Epidemiol
. 2024 Mar;
34(10):485-492.
PMID: 38462528
Background: This study aimed to develop and validate claims-based algorithms for identifying hospitalized patients with coronavirus disease 2019 (COVID-19) and disease severity. Methods: We used claims data including all patients...
6.
Mimura W, Ishiguro C, Terada-Hirashima J, Matsunaga N, Maeda M, Murata F, et al.
Open Forum Infect Dis
. 2023 Oct;
10(10):ofad475.
PMID: 37869405
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron BA.5 became prevalent in July 2022 in Japan. Bivalent messenger RNA (mRNA) vaccines were approved as booster doses for individuals who...
7.
Mimura W, Ishiguro C, Terada-Hirashima J, Matsunaga N, Sato S, Kawazoe Y, et al.
J Epidemiol
. 2023 Sep;
34(6):278-285.
PMID: 37743530
Background: We evaluated the effectiveness of the BNT162b2 vaccine against infection, symptomatic infection, and hospitalization in older people during the Delta-predominant period (July 1 to September 30, 2021). Methods: We...
8.
Ishiguro C, Mimura W, Uemura Y, Maeda M, Murata F, Fukuda H
Open Forum Infect Dis
. 2023 Jul;
10(7):ofad274.
PMID: 37404955
Background: This study was performed to assess the increased risk of herpes zoster (HZ) associated with mRNA vaccines for coronavirus disease 2019. Methods: This population-based cohort study was conducted in...
9.
Mimura W, Shinjo D, Shoji K, Fushimi K
Antimicrob Steward Healthc Epidemiol
. 2023 Feb;
3(1):e24.
PMID: 36819770
Objective: Defined daily-dose (DDD)-based metrics are frequently used to measure antibiotic consumption. However, they are unsuitable for the pediatric population because they are defined using the maintenance dose for 70-kg...
10.
Mimura W, Ishiguro C, Maeda M, Murata F, Fukuda H
Open Forum Infect Dis
. 2023 Jan;
9(12):ofac636.
PMID: 36589480
Background: Vaccine effectiveness against the severe acute respiratory syndrome coronavirus 2 Omicron BA.2 sublineage in Japan is unknown. We assessed the effectiveness of a third dose of COVID-19 mRNA vaccine...